BitGo Holdings (NYSE: BTGO) is rated Buy with a 12-month price target of $10-11, suggesting a 25-37% upside from its current price of around $8.03. The company’s true net revenue is approximately $170 million annually, significantly lower than the $17 billion headline figure, but it is moving towards profitability with a goal to break even in Q3. BitGo’s valuation and strategic flexibility are supported by its federal trust bank charter, no debt, and cash plus bitcoin holdings worth about $312 million after recent deals and buybacks. Key risks include ongoing unprofitability, dependence on crypto prices, legal challenges, management changes, and client concentration.
BitGo Holdings' recent performance is noted alongside Pluang's market data for context. For readers following US stocks on Pluang as of Sep 28, 2026 19:41 WIB, 32 of 150 stocks rose while 117 fell. Among movers, FIRY gained 4.59% to USD 12.99 with a typical hold time of 13 days, contrasting with KGC and NEM which declined 4.55% and 4.47% to USD 23.91 and USD 116.00, held typically for 52 and 58 days respectively.
Vertex Pharmaceuticals reported a 12% revenue increase to $3.33 billion in Q2, driven by its dominant cystic fibrosis treatments. UBS raised its price target from $585 to $615, reflecting confidence in Vertex's strong financials and growth potential....
Accenture's stock surged 37.6% recently, driven by rising demand for AI services and new AI-focused offerings. The company outpaced industry growth and secured 100 new clients for advanced AI projects in one quarter. An analyst raised the price targe...
SpaceX, trading near $148 per share with a market cap of about $1.95 trillion, is preparing for Starship's first orbital mission and the deployment of its first operational Starlink V3 satellites. This milestone is key for expanding Starlink's global...
Argus Research initiated coverage on 10x Genomics with a Buy rating and a $110 price target, suggesting a 28% upside from its current price of around $85. The stock shows strong momentum, trading well above its 50-day and 200-day moving averages. How...
Morgan Stanley reaffirmed an "Overweight" rating on Cullen/Frost Bankers, Inc., raising its price target to $201, signaling confidence in the bank's prospects. Major institutional investors like State Street Corp and BlackRock have increased or initi...
